CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising prevalence of autoimmune diseases
4.1.2. Growing initiatives by the government and pharmaceutical companies
4.1.3. Rising public awareness of the availability of various alternatives for treatment
4.1.4. Increasing number product approval and launches
4.2. Market Restraints & Challenges
4.2.1. Rising concerns over quality and standardisation of immunoassay kits
4.2.2. Limitation of autoimmune disease treatment
4.3. Market Opportunities
4.3.1. The shift from monoplex testing to multiplex testing
CHAPTER 5 GLOBAL AUTOIMMUNE TREATMENT MARKET – BY PRODUCT
5.1. Diagnostic Equipment
5.2. Drugs
5.2.1. Steroidal Inflammatory Drugs
5.2.2. Glucocorticoids
5.2.3. Methotrexate
5.2.4. Anthralin
5.2.5. Avonex
5.2.6. Hydroxychloroquine
5.2.7. DMARD
5.2.8. Rebif
5.2.9. Betaseron
5.2.10. 5-ASA
5.2.11. Others
5.3. Therapy & Monitoring Equipment
CHAPTER 6 GLOBAL AUTOIMMUNE TREATMENT MARKET – BY
TECHNOLOGY
6.1. Bridge Therapy
6.2. Photo Therapy
6.3. Topical Therapy
6.4. Faecal Bacteriotherapy
6.5. Recombinant Technology
6.6. Helminthic Therapy
6.7. Hematopoietic Stem Cell Transplantation
6.8. Others
CHAPTER 7 GLOBAL AUTOIMMUNE TREATMENT MARKET – BY
APPLICATION
7.1. Localised Autoimmune Diseases
7.2. Systemic Autoimmune Diseases
7.2.1. Rheumatoid Arthritis
7.2.2. Psoriasis
7.2.3. Lupus
7.2.4. Type-I Diabetes
7.2.5. Inflammatory Bowel Disease
7.2.6. Thyroid Disorders
CHAPTER 8 GLOBAL AUTOIMMUNE TREATMENT MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9 GLOBAL AUTOIMMUNE TREATMENT MARKET - COMPANY
PROFILES
9.1. Abbott Laboratories
9.2. Bristol-Myers Squibb Company
9.3. Amgen Inc.
9.4. Bayer AG
9.5. Eli Lilly and Company
9.6. Bio-Rad Laboratories, Inc.
9.7. Pfizer Inc.
9.8. GlaxoSmithKline PLC
9.9. Boehringer Ingelheim GmbH
9.10. AstraZeneca PLC
9.11. Astellas Pharma Inc.
9.12. Johnson & Johnson Services Inc.
9.13. F. Hoffmann-La Roche AG
9.14. Merck & Co. Inc.,
9.15. Biogen
CHAPTER 10 GLOBAL AUTOIMMUNE TREATMENT MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11 MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12 APPENDIX
12.1. List of Tables
12.2. List of Figures
